Zhitong Finance App News, Weilizhibo-B (09887.HK) announced that the first patient was enrolled in an open, multi-center phase IB/II clinical trial of Velisin® (opatisumimab, PD-L1/4-1BB bispecific antibody) combined medication developed independently by the Evaluation Group to treat metastatic colorectal cancer (mCRC). This marks a further extension of the company's strategy to target immunity against “cold tumors” with Velisign®, from extrapulmonary neuroendocrine cancer (“EP-NEC”), biliary tract cancer (“BTC”), hepatocellular carcinoma (“HCC”), and platinum-resistant ovarian cancer (“PROC”).

Zhitong Finance App News, Weilizhibo-B (09887.HK) announced that the first patient was enrolled in an open, multi-center phase IB/II clinical trial of Velisin® (opatisumimab, PD-L1/4-1BB bispecific antibody) combined medication developed independently by the Evaluation Group to treat metastatic colorectal cancer (mCRC). This marks a further extension of the company's strategy to target immunity against “cold tumors” with Velisign®, from extrapulmonary neuroendocrine cancer (“EP-NEC”), biliary tract cancer (“BTC”), hepatocellular carcinoma (“HCC”), and platinum-resistant ovarian cancer (“PROC”).